229 related articles for article (PubMed ID: 29050695)
1. How is the Ph-like signature being incorporated into ALL therapy?
Maese L; Tasian SK; Raetz EA
Best Pract Res Clin Haematol; 2017 Sep; 30(3):222-228. PubMed ID: 29050695
[TBL] [Abstract][Full Text] [Related]
2. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
3. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
Wells J; Jain N; Konopleva M
Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
[TBL] [Abstract][Full Text] [Related]
4. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
Short NJ; Kantarjian H; Jabbour E; Ravandi F
Best Pract Res Clin Haematol; 2017 Sep; 30(3):193-200. PubMed ID: 29050692
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
6. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts.
Ganguly S; Sasi A; Pushpam D; Bakhshi S
Indian J Pediatr; 2024 Jan; 91(1):37-46. PubMed ID: 37632689
[TBL] [Abstract][Full Text] [Related]
7. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
8. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
9. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Wieduwilt MJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
[TBL] [Abstract][Full Text] [Related]
10. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
15. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
16. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Shen S; Chen X; Cai J; Yu J; Gao J; Hu S; Zhai X; Liang C; Ju X; Jiang H; Jin R; Wu X; Wang N; Tian X; Pan K; Jiang H; Sun L; Fang Y; Li CK; Hu Q; Yang M; Zhu Y; Zhang H; Li C; Pei D; Jeha S; Yang JJ; Cheng C; Tang J; Zhu X; Pui CH
JAMA Oncol; 2020 Mar; 6(3):358-366. PubMed ID: 31944221
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Appelmann I; Rillahan CD; de Stanchina E; Carbonetti G; Chen C; Lowe SW; Sherr CJ
Blood; 2015 Feb; 125(9):1444-51. PubMed ID: 25499760
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome-like Relapsed/Refractory acute lymphoblastic leukemia.
Bayram N; Yaman Y; Özdilli K; Telhan L; Nepesov S; Bilgen H; Elli M; Behar SS; Anak S
Pediatr Transplant; 2021 Jun; 25(4):e14024. PubMed ID: 33860589
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
